GLP-1 TV · News & media · 9 videos
CNBC Television
@CNBCtelevision on YouTube ↗CNBC Television is a YouTube channel of news and media coverage of GLP-1 medications, with 3.4M subscribers and a verified badge. GLP-1 TV holds 9 of its videos, 160K views between them, the newest from Feb 2026. The speaker in most of them is Brandon Gomez, as the videos introduce them.
- Medications covered
- Ozempic (2), Wegovy (2), Wegovy pill (1)
- Topics that come up most
- The trials, Side effects, Cost and insurance, How it works, Stopping and maintenance, Weigh-in and results
9:09Dr. Scott Gottlieb on Novo Nordisk vs. Hims & Hers: We have a drug approval process for a reasonCNBC TelevisionDetails5 key moments
CNBC's hosts talk with Dr. Scott Gottlieb, a CNBC contributor and former FDA commissioner, about the dispute between Novo Nordisk and Hims & Hers over an oral GLP-1 pill.
- 0:00 GLP-1 drug dispute
- 0:35 FDA actions on technology
- 2:14 Risks of unapproved drugs
- 4:28 Market competition and strategy
- 6:12 Vaccine safety and policy
- Who is speaking: News or media
5:49Ozempic & Wegovy may be linked to eye condition, vision loss: StudyCNBC TelevisionDetails4 key moments
According to the video, a new study suggests that people taking Ozempic and Wegovy may have a higher risk of a condition that can cause irreversible vision loss. The study's author says more research is needed to confirm any link.
- 0:00 Study on weight loss drugs
- 1:32 Potential eye side effects
- 2:40 Understanding the mechanisms
- 3:37 Indications and usage risks
- Who is speaking: News or media
3:44New study reveals why patients stop taking GLP-1 obesity drugsCNBC TelevisionDetails7 key moments
This CNBC Television segment features Trisha Rodriguez, identified as the lead author of a first-of-its-kind study on why patients stop or restart GLP-1 obesity drug treatment.
- 0:00 GLP-1 discontinuation study
- 0:20 Weight loss impact
- 0:52 Income and cost factors
- 1:11 Diabetes and cost burdens
- 1:40 Quantifying weight loss
- 2:18 Key study takeaways
- 2:40 Improving patient access
- Who is speaking: News or media
4:40Dr. Craig Primack talks Hims & Hers launching its own GLP-1 offering as demand risesCNBC TelevisionDetails
According to the video, Hims & Hers shares rose 27% on the day the company announced a compounded GLP-1 injection that patients can reach through providers on its platform.
- Prices mentioned: $199 a month and $500 a month
- Who is speaking: News or media
1:29Novo Nordisk’s Canadian drug patent lapses, opening market for Hims & Her HealthCNBC TelevisionDetails3 key moments
According to this CNBC segment, Novo Nordisk will lose its exclusive Canadian patent on semaglutide, the ingredient in its top-selling drugs Ozempic and Wegovy, next January. The reporter, Brandon Gomez, says the cause was an unpaid $450 licensing fee.
- Who is speaking: News or media
11:00Don't place your hopes on Hims & Hers GLP-1 business, says Jim CramerCNBC TelevisionDetails7 key moments
In this Mad Money segment, Jim Cramer reviews Hims & Hers Health, a digital health platform that, according to the video, covers sexual health, skin care, mental health and weight loss.
- 0:00 Hims & Hers business overview
- 2:02 Strong earnings and growth
- 3:46 Weight loss drug catalyst
- 4:50 Negative report impact
- 6:41 Investment thesis analysis
- 7:22 Lightning round queries
- 10:09 Final market thoughts
- Prices mentioned: $109 a month
- Who is speaking: News or media
4:52Ozempic, Wegovy trials show positive results for Dementia, alcohol addictionCNBC TelevisionDetails4 key moments
In this CNBC interview, Dr Scott Gottlieb, a CNBC contributor and former FDA commissioner, discusses early signs that Ozempic and Wegovy type drugs may help with conditions beyond weight loss, specifically Alzheimer's disease and alcohol addiction.
- Side effects mentioned: nausea
- Who is speaking: News or media
3:12Cost will be key for Novo Nordisk's Wegovy pill, says Dr. PatelCNBC TelevisionDetails3 key moments
In this CNBC Television segment, Dr. Kavita Patel, described as an NBC News and MSNBC medical contributor, is asked whether Novo Nordisk has pulled ahead of Lilly after a shift in investor sentiment following a conference in Vienna.
- Who is speaking: News or media
1:30Hims & Hers launches into Canada as country prepare for generic GLP-1 weight loss drugsCNBC TelevisionDetails
According to the video, a CNBC report says Hims & Hers Health is expanding into Canada by completing an all-cash acquisition of Livewell, a Canadian digital health provider known for weight loss care.
- Who is speaking: News or media
Where semaglutide costs least today
The three cheapest partner programs for semaglutide, all in per month, checked weekly. Brand Ozempic and compounded versions are different products; each row says which it is.
What each CNBC Television video covers
The opening line of our summary for each video, most-watched first.
- Dr. Scott Gottlieb on Novo Nordisk vs. Hims & Hers: We have a drug approval process for a reason
CNBC's hosts talk with Dr. Scott Gottlieb, a CNBC contributor and former FDA commissioner, about the dispute between Novo Nordisk and Hims & Hers over an oral GLP-1 pill.
43.8K views · Feb 2026 - Ozempic & Wegovy may be linked to eye condition, vision loss: Study
According to the video, a new study suggests that people taking Ozempic and Wegovy may have a higher risk of a condition that can cause irreversible vision loss.
32.9K views · Jul 2024 - New study reveals why patients stop taking GLP-1 obesity drugs
This CNBC Television segment features Trisha Rodriguez, identified as the lead author of a first-of-its-kind study on why patients stop or restart GLP-1 obesity drug treatment.
19.9K views · Jan 2025 - Dr. Craig Primack talks Hims & Hers launching its own GLP-1 offering as demand rises
According to the video, Hims & Hers shares rose 27% on the day the company announced a compounded GLP-1 injection that patients can reach through providers on its platform.
17.1K views · May 2024 - Novo Nordisk’s Canadian drug patent lapses, opening market for Hims & Her Health
According to this CNBC segment, Novo Nordisk will lose its exclusive Canadian patent on semaglutide, the ingredient in its top-selling drugs Ozempic and Wegovy, next January.
14.7K views · Jul 2025 - Don't place your hopes on Hims & Hers GLP-1 business, says Jim Cramer
In this Mad Money segment, Jim Cramer reviews Hims & Hers Health, a digital health platform that, according to the video, covers sexual health, skin care, mental health and weight loss.
14.6K views · Jul 2024 - Ozempic, Wegovy trials show positive results for Dementia, alcohol addiction
In this CNBC interview, Dr Scott Gottlieb, a CNBC contributor and former FDA commissioner, discusses early signs that Ozempic and Wegovy type drugs may help with conditions beyond weight loss, specifically Alzheimer's disease and alcohol addiction.
11.9K views · Sep 2023 - Cost will be key for Novo Nordisk's Wegovy pill, says Dr. Patel
In this CNBC Television segment, Dr. Kavita Patel, described as an NBC News and MSNBC medical contributor, is asked whether Novo Nordisk has pulled ahead of Lilly after a shift in investor sentiment following a conference in Vienna.
2.9K views · Sep 2025 - Hims & Hers launches into Canada as country prepare for generic GLP-1 weight loss drugs
According to the video, a CNBC report says Hims & Hers Health is expanding into Canada by completing an all-cash acquisition of Livewell, a Canadian digital health provider known for weight loss care.
2.7K views · Dec 2025
Watched them? See what it costs.
Every GLP-1 program we track, ranked by what actually leaves your account.